LATAM MedTech Insights cover art

LATAM MedTech Insights

LATAM MedTech Insights

Written by: Ran Chen
Listen for free

About this listen

 Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.Copyright 2026 Ran Chen Biological Sciences Economics Science
Episodes
  • Brazil's ANVISA Digital Chaos: Pure Global on High-Risk Device Submission Secrets

    Brazil's ANVISA Digital Chaos: Pure Global on High-Risk Device Submission Secrets
    Mar 1 2026
    In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market. We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil. Key Questions Answered: 1. What are the three biggest technical mistakes companies make on the new ANVISA portal? 2. How does this digital shift affect submission timelines for Class III and IV devices? 3. Are there any unannounced changes to the technical dossier requirements? 4. How can you leverage this change to potentially speed up your approval process? 5. What does this move signal about ANVISA's long-term regulatory strategy? 6. Is your local distributor truly equipped to handle this level of regulatory complexity? 7. How will this impact foreign manufacturers compared to local Brazilian companies? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at info@pureglobal.com or learn more by visiting https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.

    Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.
    Feb 28 2026
    This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market. **Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality? **Key Questions Answered:** * What specific cybersecurity standards has ANVISA now mandated for all SaMD products? * How does the new guidance re-classify your AI-powered medical software? * Are your existing clinical validation studies sufficient for the new Brazilian requirements? * What are the three most common documentation pitfalls for foreign firms under the new guidelines? * Why is appointing a local Brazil Registration Holder now more critical than ever? * How can you turn Brazil's tough new regulations into a strategic advantage? At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil & Mexico's MedTech Manufacturing - The Local Production Gambit.

    Pure Global: Brazil & Mexico's MedTech Manufacturing - The Local Production Gambit.
    Feb 27 2026
    This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region. What you'll learn in this episode: - Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America? - What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico? - How can a company leverage local manufacturing to gain a competitive advantage? - What is the number one mistake companies make when aligning with ANVISA's manufacturing practices? - Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices? - How does in-country production change the strategy for post-market surveillance? - What specific government incentives are most attractive for new MedTech manufacturers in 2026? Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
No reviews yet